Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Chlorpromazine overcomes temozolomide resistance in glioblastoma by inhibiting Cx43 and essential DNA repair pathways

18 Jul 2024

Abstract excerpt

BACKGROUND: In the fight against GBM, drug repurposing emerges as a viable and time-saving approach to explore new treatment options. Chlorpromazine, an old antipsychotic medication, has recently arisen as a promising candidate for repositioning in GBM therapy in addition to temozolomide, the first-line standard of care. We previously demonstrated the antitumor efficacy of chlorpromazine and its synergistic...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Connexins and lens biology
Share to DNA Repair Mechanisms
Share to PARP inhibition in cancer therapy

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 39026284
DOI: 10.1186/s12967-024-05501-3

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 8 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Chlorpromazine overcomes temozolomide resistance in glioblastoma by inhibiting Cx43 and essential DNA repair pathwaysPMID 39026284Read ↗

Chlorpromazine Overcomes Temozolomide Resistance in Glioblastoma by inhibiting Cx43 and Essential DNA Repair PathwaysSemantic proximity Read ↗

Chlorpromazine Induces Cytotoxic Autophagy in Glioblastoma Cells via Endoplasmic Reticulum Stress and Unfolded Protein ResponseSemantic proximity Read ↗

Repurposing chlorpromazine as add-on in the adjuvant phase of first-line glioblastoma therapeutic protocol in patients carrying hypo-/un-methylated<i>MGMT</i>gene promoter: RACTAC, a Phase II multicenter single-arm clinical trialSemantic proximity Read ↗

Connexin43 confers Temozolomide resistance in human glioma cells by modulating the mitochondrial apoptosis pathway.Semantic proximity Read ↗

Chloroquine inhibits the malignant phenotype of glioblastoma partially by suppressing TGF-beta.Semantic proximity Read ↗

Inhibition of DNA-repair genes Ercc1 and Mgmt enhances temozolomide efficacy in gliomas treatment: a pre-clinical studySemantic proximity Read ↗

Multifaceted effect of chlorpromazine in cancer: implications for cancer treatmentSemantic proximity Read ↗

Novel Imidazotetrazine Evades Known Resistance Mechanisms and Is Effective against Temozolomide-Resistant Brain Cancer in Cell CultureSemantic proximity Read ↗

Epigenetic preconditioning with decitabine sensitizes glioblastoma to temozolomide via induction of MLH1Semantic proximity Read ↗

Repair of 3-methyladenine and abasic sites by base excision repair mediates glioblastoma resistance to temozolomideSemantic proximity Read ↗

Clinical and Genetic Factors Associated With Severe Hematological Toxicity in Glioblastoma Patients During Radiation Plus Temozolomide Treatment: A Prospective Study.Semantic proximity Read ↗

Thioridazine inhibits autophagy and sensitizes glioblastoma cells to temozolomideSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.